Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating belantamab mafodotin in combination with daratumumab, lenalidomide, and dexamethasone for newly diagno…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older [Phase 2]
Phase 2 trial comparing autologous stem cell transplant with high-dose melphalan versus high-dose melphalan plus bortezomib in patients aged…
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) [Phase 2]
Phase 2 trial update on BRAF/MEK inhibition for relapsed/refractory multiple myeloma with BRAFV600E/K mutations.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on monoclonal antibody-based sequential therapy aiming for deep remission in multiple myeloma; results posted …
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial evaluating a COVID-19 vaccine booster dosing in patients with hematologic malignancies has completed enrollment and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A study update for CM313 in relapsed or refractory multiple myeloma spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating SL-401 in combination with pomalidomide and dexamethasone in relapsed or relapsed/refractory multiple myeloma was…
-
CLINICAL_TRIALS trial_result · 2023-11-08Clinical Trial Update: Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet [Phase 2]
Phase 2 trial in early relapsed, lenalidomide-refractory multiple myeloma evaluated a carfilzomib-based triplet regimen; results have been p…
-
CLINICAL_TRIALS trial_result · 2023-11-08Clinical Trial Update: Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma [Phase 2]
A Phase 2 clinical trial assessed whether hyperbaric oxygen improves blood count recovery after autologous stem cell transplantation in mult…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Short Course Daratumumab in Patients With Multiple Myeloma [Phase 2]
This report summarizes Phase 2 results for a short-course daratumumab regimen in patients with multiple myeloma, with the trial completed an…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) [Phase 3]
Phase III trial evaluating BL-8040 (motixafortide) with G-CSF versus placebo with G-CSF for mobilizing hematopoietic stem cells in autologou…
-
CLINICAL_TRIALS trial_result · 2023-11-03Clinical Trial Update: Lapelga vs Gastrofil [Phase 3]
Phase 3 trial update for Lapelga versus Gastrofil in patients with Multiple Myeloma and Lymphoma; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating ixazomib as a replacement for carfilzomib and bortezomib in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-10-27Clinical Trial Update: Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on Auto-Allo Tandem Stem Cell Transplantation for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: KRDI in Transplant-Eligible MM [Phase 2]
A Phase 2 study of KRDI in transplant-eligible multiple myeloma has posted results and the trial remains active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb [Phase 2]
This is a Phase 2 study of elranatamab (PF-06863135) as a monotherapy in adults with multiple myeloma who are refractory to a proteasome inh…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients [Phase 2]
Phase 2 trial investigating selinexor with clarithromycin, pomalidomide, and dexamethasone for relapsed refractory multiple myeloma; study t…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating APG-2575 in combination regimens for relapsed or refractory multiple myeloma and amyloidosis.
-
CLINICAL_TRIALS trial_result · 2023-10-24Clinical Trial Update: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Blmf, Lenalidomide, and Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma patients…
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients [Phase 2]
Phase 2 trial evaluating nonmyeloablative allogeneic stem cell transplantation followed by bortezomib in high-risk multiple myeloma patients…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating leflunomide in patients with relapsed or refractory multiple myeloma has completed with results posted…
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 3]
Phase 3 trial comparing single-agent belantamab mafodotin to pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myelom…
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial of bendamustine with bortezomib and pegylated liposomal doxorubicin in multiple myeloma was terminated.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Methods of T Cell Depletion Trial (MoTD) [Phase 2]
Phase 2 trial update for methods of T cell depletion in various hematologic malignancies is ongoing.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning donor stem cell transplantation for relapsed multiple myeloma has been terminated; r…